Drugs / SB-743921
SB-743921
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00136513 | Apr 2004 → ? | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00343564 | Apr 2006 → Jul 2010 | Hodgkins lymphoma, non-Hodgkin lymphoma | Cytokinetics | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB-743921 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00343564 ↗ |
| Known as | SB-743921 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2325429 ↗ |
| Known as | SB-921 | “This was a phase I study of SB-743921 (SB-921) in patients with relapsed/refractory lymphoma.” PMID 25665464 ↗ Sep 2015 |
| Action | Inhibit | “kinesin spindle protein inhibitor SB-743921” PMID 25665464 ↗ Sep 2015 |
| Modality | Small molecule | — CHEMBL2325429 ↗ |
| Route | Intravenous | “intravenous infusion” NCT00136513 ↗ |